Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Intermountain Healthcare Strike Precision Cancer Research Alliance

This article has been updated from a previous version which incorrectly stated that the collaboration is focused on patient care rather than precision cancer research.

NEW YORK — Tempus said on Thursday that it has partnered with healthcare system Intermountain Healthcare to generate molecular data for personalized cancer research.

Under the collaboration, Salt Lake City-based Intermountain will use Tempus' xT broad-panel genomic sequencing assay, which is designed to detect alterations by matching tumor sequencing to normal saliva or blood, to generate whole transcriptomic data on existing samples to advance its research intended to advance patient care and outcomes.

Tempus said it will also structure and harmonize Intermountain's deidentified clinical and molecular datasets to increase their accessibility for researchers.

Financial and other terms of the deal were not disclosed.

Earlier this month, Chicago-based Tempus struck an alliance with Eli Lilly to offer xT and certain other cancer tests at no cost to physicians treating advanced non-small cell lung cancer patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.